{"id":"transdermal-clonidine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Dry mouth"},{"rate":"30-40","effect":"Drowsiness"},{"rate":"15-25","effect":"Dizziness"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Constipation"},{"rate":"15-20","effect":"Skin irritation at patch site"},{"rate":"5-10","effect":"Rebound hypertension upon discontinuation"}]},"_chembl":null,"_dailymed":{"setId":"05d520bf-3ab7-4337-9f38-4418e5e7e1e9","title":"CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY (CLONIDINE TRANSDERMAL SYSTEM) PATCH CLONIDINE TRANSDERMAL SYSTEM USP, 0.2 MG/DAY (CLONIDINE TRANSDERMAL SYSTEM) PATCH CLONIDINE TRANSDERMAL SYSTEM USP, 0.3 MG/DAY (CLONIDINE TRANSDERMAL SYSTEM) PATCH [TRUPHARMA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, decreasing the release of norepinephrine and reducing sympathetic outflow. The transdermal formulation provides sustained drug delivery through the skin, maintaining therapeutic levels over extended periods. This mechanism results in vasodilation and reduced cardiac output, leading to antihypertensive effects.","oneSentence":"Transdermal clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:33:17.662Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT06807164","phase":"PHASE2","title":"Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2026-03-31","conditions":"Post-Mastectomy Neuropathic Pain Syndrome","enrollment":123},{"nctId":"NCT01422616","phase":"PHASE3","title":"Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2012-03","conditions":"Ischemic Stroke, High Blood Pressure","enrollment":4587},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01139996","phase":"PHASE4","title":"Use of Transdermal Clonidine in Trauma Patients","status":"TERMINATED","sponsor":"Memorial Health University Medical Center","startDate":"2010-05","conditions":"Delirium","enrollment":22},{"nctId":"NCT01082874","phase":"PHASE3","title":"PeriOperative ISchemic Evaluation-2 Trial","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2010-07","conditions":"Cardiovascular Disease","enrollment":10010},{"nctId":"NCT02545530","phase":"NA","title":"Transdermal Clonidine in Chronic Hemodialysis Patients","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-05","conditions":"Renal Dialysis","enrollment":45},{"nctId":"NCT02096744","phase":"PHASE1","title":"Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Healthy","enrollment":56},{"nctId":"NCT02410460","phase":"NA","title":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","startDate":"2013-09","conditions":"Rhytidoplasty","enrollment":30},{"nctId":"NCT01559012","phase":"PHASE3","title":"Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2012-02","conditions":"Hyperemesis Gravidarum","enrollment":13},{"nctId":"NCT00716079","phase":"NA","title":"The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2008-09","conditions":"Intracerebral Hemorrhage, Stroke, Hypertension","enrollment":2839},{"nctId":"NCT00413582","phase":"NA","title":"Pain Management for Pectus Excavatum Repair","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2006-10","conditions":"Postoperative Pain","enrollment":110},{"nctId":"NCT00860925","phase":"PHASE4","title":"PeriOperative ISchemic Evaluation-2 Pilot","status":"COMPLETED","sponsor":"McMaster University","startDate":"2009-05","conditions":"Cardiovascular Disease","enrollment":90},{"nctId":"NCT00335582","phase":"PHASE4","title":"EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine)","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2006-06","conditions":"Heart Disease","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"transdermal clonidine","genericName":"transdermal clonidine","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Transdermal clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}